GPC3 and ovarian cancer: The results of this trial relating to the treatment of ovarian cancer patients are yet to be obtained; however, these researchers reported that intratumoral administration of the IL-7/CCL19-engineered glypican 3-redirected CAR-Ts led to complete tumor eradication a month following the treatment in a patient with hepatocellular carcinoma (151).